$3.21
1.90%
Nasdaq, Oct 01, 12:28 pm EDT. Market open.
ISIN
US52886N4060
Symbol
LEXX

Lexaria Bioscience Corp Target price 2026 - Analyst rating & recommendation

Lexaria Bioscience Corp Classifications & Recommendation

Buy
86%
Hold
14%

Lexaria Bioscience Corp Price Target

Target Price $53.55
Price $3.15
Potential
Number of Estimates 4
4 Analysts have issued a price target Lexaria Bioscience Corp 2027 . The average Lexaria Bioscience Corp target price is $53.55. This is higher than the current stock price. The highest price target is
$86.63 2,650.00%
register free of charge
, the lowest is .
A rating was issued by 7 analysts: 6 Analysts recommend Lexaria Bioscience Corp to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Lexaria Bioscience Corp stock has an average upside potential 2027 of . Most analysts recommend the Lexaria Bioscience Corp stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Aug '25 2026
Estimates
Revenue Million $ 0.71 0.02
54.35% 97.13%
Net Margin -1,676.06% -5,445.00%
32.93% 224.87%

4 Analysts have issued a sales forecast Lexaria Bioscience Corp 2026 . The average Lexaria Bioscience Corp sales estimate is

$20.4k
unlock
. This is
89.26% lower
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$21.0k 88.95%
unlock
, the lowest is
$19.6k 89.68%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $710k 54.35%
2026
$20.4k 97.13%
unlock
2027
$1.4m 6,914.71%
unlock
2028
$1.6m 13.00%
unlock
2029
$71.6m 4,327.33%
unlock
2030
$139m 94.15%
unlock
2031
$184m 32.56%
unlock
2032
$231m 25.56%
unlock

3 Lexaria Bioscience Corp Analysts have issued a net profit forecast 2026. The average Lexaria Bioscience Corp net profit estimate is

$-1.1m
unlock
. This is
85.64% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-1.1m 86.16%
unlock
, the lowest is
$-1.1m 85.25%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-11.9m 105.17%
2026
$-1.1m 90.67%
unlock
2027
$-7.8m 605.41%
unlock
2028
$-7.1m 9.71%
unlock

Net Margin

2025 -1,676.06% 32.93%
2026
-5,445.00% 224.87%
unlock
2027
-546.89% 89.96%
unlock
2028
-437.14% 20.07%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Aug '25 2026
Estimates
Earnings Per Share $ -9.92 -0.67
41.31% 93.25%
P/E negative
EV/Sales 148.04

3 Analysts have issued a Lexaria Bioscience Corp forecast for earnings per share. The average Lexaria Bioscience Corp EPS is

$-0.67
unlock
. This is
85.65% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.69 85.22%
unlock
, the lowest is
$-0.65 86.08%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-9.92 41.31%
2026
$-0.67 93.25%
unlock
2027
$-4.74 607.46%
unlock
2028
$-4.28 9.70%
unlock

P/E ratio

Current -0.67 60.17%
2026
-4.68 593.85%
unlock
2027
-0.66 85.90%
unlock
2028
-0.74 12.12%
unlock

Based on analysts' sales estimates for 2026, the Lexaria Bioscience Corp stock is valued at an EV/Sales of

148.04
unlock
and an P/S ratio of
325.49
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 15.87 38.15%
2026
148.04 832.82%
unlock
2027
2.11 98.57%
unlock
2028
1.87 11.50%
unlock
2029
0.04 97.74%
unlock
2030
0.02 48.58%
unlock
2031
0.02 24.42%
unlock
2032
0.01 20.12%
unlock

P/S ratio

Current 34.92 5.43%
2026
325.49 832.01%
unlock
2027
4.64 98.57%
unlock
2028
4.11 11.50%
unlock
2029
0.09 97.74%
unlock
2030
0.05 48.49%
unlock
2031
0.04 24.69%
unlock
2032
0.03 20.28%
unlock

Current Lexaria Bioscience Corp Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
➜
Locked
Locked Dec 26 2025
HC Wainwright & Co.
Locked
➜
Locked
Locked Jul 29 2025
HC Wainwright & Co.
Locked
➜
Locked
Locked Jul 01 2025
HC Wainwright & Co.
Locked
➜
Locked
Locked Jan 24 2025
HC Wainwright & Co.
Locked
➜
Locked
Locked Dec 02 2024
HC Wainwright & Co.
Locked
➜
Locked
Locked Nov 25 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Dec 26 2025
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Jul 29 2025
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Jul 01 2025
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Jan 24 2025
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Dec 02 2024
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Nov 25 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today